Europe Point of Care Testing Devices Market is Expected to Reach EUR 7.2 Billion by 2022 Owing to Promising Growth in Demand of Infectious, Cardiac and Drug of Abuse POCT Devices: Ken Research
Western European countries especially Germany, Italy and United Kingdom have led the market in Europe in terms of manufacturing & consumption of POCT devices. Application of POCT devices in diverse fields of defence, forensics and oncology has led the market in the region.
Mergers and acquisitions (M&A) has been a crucial competitive strategy for players to capture higher market share, access new technology and to expand product offerings in Europe. Data management of POCT has emerged as an upcoming revenue stream for these companies.
Blood Glucose POCT, Infectious POCT and Cardiac POCT would be the leading product segments in terms of sales by the end of the forecast period.
POCT market in Europe has been estimated to grow registering a CAGR of close to 6% in the forecast period. This growth would be supported by the launch of new products, entry of new players, innovative technological revolution and increase in reliability on POCT products by home patients & institutional buyers. Technology innovation in molecular diagnostics is a major driver within the infectious disease POCT for HAIs and STDs. HIV-1, HCV, c.difficle, Chlamydia, H. Pylori, Strep A/B, Influenza A/B, RSV, Ebola and Zika have widespread in Europe during the review period. Highly sensitive cardiac troponins that are the efficacy equivalent to centralized lab testing will increase the adoption of POC cardiac markers in POC settings. CK-MB, myoglobin, BNP, NT-proBNP and D-dimers are simultaneously being used in emergency settings. Inevitable pharamcoeconomic benefits in POC cardiac testing propels this segment to achieve its highest growth potential. Increase in reliability & trust in POCT devices by home users & hospitals, more incidence of diseases such as HIV, infectious, cardiac and others, increase in the number of hospitals, clinics, pathology labs in Europe, growth in nano technology and chip-on-phone miniaturization would provide major thrust to the market.
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.
To access the call by phone, please go to this registration link and you...
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a...